Emerging MS Treatments: Reading the Gilenya Tea Leaves
This article was originally published in Start Up
Executive Summary
The closely watched launch of Gilenya, the first oral treatment for multiple sclerosis, may have changed the game for developing new therapies for the disease. Start-Up profiles four emerging MS drug developers: Allozyne, GeNeuro, Nuron Biotech and Receptos.
You may also be interested in...
Teva Swoops In To Snatch Cephalon For $6.7 Billion
Cephalon, the mid-sized specialty pharma company has found a white knight. Just two weeks before a May 12 deadline required shareholders to tender their shares for or against a takeover offer by Valeant Pharmaceuticals International, the company has accepted a $6.8 billion cash offer from Teva Pharmaceutical Industries.
Teva Swoops In To Snatch Cephalon For $6.7 Billion
Cephalon, the mid-sized specialty pharma company has found a white knight. Just two weeks before a May 12 deadline required shareholders to tender their shares for or against a takeover offer by Valeant Pharmaceuticals International, the company has accepted a $6.8 billion cash offer from Teva Pharmaceutical Industries.
Receptos Inc.
Receptos isn't the only company in the G-coupled protein receptor oral MS drug arena, but it believes its proprietary S1P1 agonist will improve on Novartis' first-in-class S1P1 modulator Gilenya. Unlike Gilenya, which hits four of the five S1P receptor subtypes, the Receptos molecule binds selectively to S1P1 and has a predicted human half-life of approximately one day, potentially improving the safety profile and reducing complications for MS patients.
Need a specific report? 1000+ reports available
Buy Reports